Skip to main content

Table 1 Comparison between baseline and 6 or 12 months after ART initiation

From: A prospective study of endothelial activation biomarkers, including plasma angiopoietin-1 and angiopoietin-2, in Kenyan women initiating antiretroviral therapy

Variable   Baseline to month 6 comparison a Baseline to month 12 comparison a,b
  Baseline median (IQR) Month 6 median (IQR) P value Month 12 median (IQR) P value
Plasma HIV-1 RNA (copies/mL) 349,066 (149,106–919,173) <100 (<100–154) <0.001 <100 (<100–176) <0.001
CD4 Cell count (cells/μL) 124 (79–164) 236 (159–323) <0.001 240 (182–332) <0.001
Angiopoietin-1 (ng/mL) 13.7 (10.2–19.1) 22.5 (16.1–30.2) <0.001 15.8 (11.6–21.9) 0.006
Angiopoietin-2 (ng/mL) 1.50 (0.37–2.43) 0.86 (0.31–1.92) 0.012 0.70 (<0.03–1.59) 0.030
ANG-2/ANG-1 ratio 0.09 (0.02–0.18) 0.03 (0.01–0.08) <0.001 0.03 (0.003–0.11) 0.002
Soluble ICAM-1 (ng/mL) 397.9 (338.0–489.7) 220.5 (185.2–292.5) <0.001 255.2 (200.0–312.5) <0.001
E-Selectin (ng/mL) 24.2 (16.6–32.3) 13.7 (7.4–20.0) <0.001 25.2 (18.5–30.4) 0.29
VCAM-1 (ng/mL) 763.8 (524.3–1107.6) 762.5 (537.0–1,013.3) 0.63 497.8 (407.2–628.6) <0.001
  1. ART antiretroviral therapy, IQR interquartile range.
  2. a Although 90 women completed the study at month 12, there was insufficient sample from one woman for testing of endothelial markers at this time-point. Therefore, there were 95 paired samples for the baseline to month 6 comparison and 89 paired samples for the baseline to month 12 comparison for all variables presented above except plasma HIV-1 RNA (90 paired samples available).
  3. b Differences between angiopoietin-1, E-selectin, and VCAM-1 levels between month 6 and month 12 were all significant at p < 0.001.